Phase Ib Study of Drozitumab Combined With First-Line mFOLFOX6 Plus Bevacizumab in Patients with Metastatic Colorectal Cancer

By Rocha Lima Caio M.   Bayraktar Soley   Flores Aurea M.   MacIntyre Jessica   Montero Alberto   Baranda Joaquina C.   Wallmark John   Portera Chia   Raja Rajiv   Stern Howard   Royer-Joo Stephanie   Amler Lukas C.  

Cancer Investigation, Vol. 30, Iss. 10, 2012-12 ,pp. : 727-731

Informa Healthcare

Access to resources Recommend Favorite

A Phase II Trial of Oxaliplatin, Folinic Acid, and 5-Fluorouracil (FOLFOX4) as First-Line Chemotherapy in Advanced Colorectal Cancer: A China Single-Center Experience

By Xu Nong   Fang Wei-Jia   Zhang Xiao-Chen   Yu Lan-Fang   Bao Han-Ying   Shi Gen-Ming   Huang Sui   Shen Peng  

Cancer Investigation, Vol. 25, Iss. 7, 2007-09 ,pp. : 599-605

Informa Healthcare

Access to resources Recommend Favorite

XELOX and bevacizumab followed by single-agent bevacizumab as maintenance therapy as first-line treatment in elderly patients with advanced colorectal cancer: the boxe study

By Rosati Gerardo   Avallone Antonio   Aprile Giuseppe   Butera Alfredo   Reggiardo Giorgio   Bilancia Domenico  

Cancer Chemotherapy and Pharmacology, Vol. 71, Iss. 1, 2013-01 ,pp. : 257-264

Springer Publishing Company

Access to resources Recommend Favorite

Comparative analysis of the efficacy and safety of modified FOLFOX-6 and DCF regimens as first-line treatment in advanced gastric cancer

By                

Molecular and Clinical Oncology, Vol. 3, Iss. 5, 2015-01 ,pp. : 1160-1164

Science Publishers

Access to resources Recommend Favorite

Oxaliplatin, 5-fluorouracil and leucovorin (modified FOLFOX-6) as first-line chemotherapy for advanced gastric cancer patients with poor performance status

By                          

Oncology Letters, Vol. 3, Iss. 2, 2012-01 ,pp. : 425-428

Spandidos Publications

Access to resources Recommend Favorite